TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Myocardial fibrosis characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Investigator-Assessed Confirmed Objective Response Rate (ORR)
Endpoint domain: Mortality/survival
Primary endpoint: Investigator-Assessed Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change from baseline in LDL-cholesterol at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in sitDBP at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maintenance of fracture reduction according to radial inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maintenance of fracture reduction according to radial height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maintenance of fracture reduction according to ulnar variance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maintenance of fracture reduction according to palmar tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in blood markers for persistent inflammatory state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in mRNA isolation and protein biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dys-HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Cholesterol-lowering efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stabilization of Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Plasma Oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Pre-dialysis Plasma Oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Michigan Hand Questionnaire (MHQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 9 Hole Peg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in brain rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in body mass index at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body fat mass at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lean body mass at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal-to-background Ratio (SBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident (non-)fatal cardiovascular diseases
Endpoint domain: Mortality/survival
Primary endpoint: Change of Peak airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Global Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of seropositive subjects for anti-pertussis toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac troponin I change measure (cTnI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seizure outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure ulcer incidence (Cat. II+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Transverse dimension of maxilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative agitation (stress)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Papilla Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic mucus thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Raw Urine Osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor radiation doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in 30 day hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in inpatient mortality
Endpoint domain: Mortality/survival
Primary endpoint: 6 Minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: echocardiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative probability of recurrent varicose vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in white matter tract structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Striatal binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Long term Verbal Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gut microbial abundant change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue coating microbial abundant change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Chemo-Radiotherapy induced pneumonitis, fibrosis and esophagus injury
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Ashworth scale for spasticity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Frequency and duration of hospital stay due to febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in DeMeester's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: immunologic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: health care related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delta Hepatitis C Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in antibiotic prescription patterns
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time-to-treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of rhEndostatin protein
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal velocity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systolic ascension time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Biomechanical stiffness (N/m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success of B+-treated dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sum of the Pain Intensity Difference at 6 hours (SPID-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-Hour Pain Intensity Scores Assessed with a Numerical Pain Rating Scale (NPRS-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DM/HT-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of DM/HT-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of DM/HT-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Service utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Glittre test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin and nasopharyngeal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with unanticipated difficult airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Picture Naming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Phrase Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Quick Mild Cognitive Impairment screen
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tapping Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joystick Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value Driven Attentional Oculomotor Capture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression (CGI) severity scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major vascular complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Major upper gastrointestinal complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Extracellular Volume Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute nonfatal cerebro-cardiovascular events before dialysis initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute nonfatal cerebro-cardiovascular events after dialysis initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of idarubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Alive and Off Oxygen at 14 Days
Endpoint domain: Mortality/survival
Primary endpoint: Repeat Blood Donation Attempts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Test of Strategic Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: All causes death
Endpoint domain: Mortality/survival
Primary endpoint: Time to achieve gross motor development milestones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IL 1-Beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of MMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Fractional Anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mean Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Radial Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Axial Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete remission of platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Thickness of Lesional Skin Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Ratio of Active Atopic Dermatitis Messenger Ribonucleic Acid (mRNA) Expression (Normalized to Human Acidic Ribosomal Protein [hARP]) in Lesional Skin Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients for Which Activation Maps Can be Created
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stroke occurrence including Transitory cerebral ischemia (TCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Response Defined Using RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glasgow Outcome Scale-Extended (GOS-E)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intracellular bacterial killing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximally tolerated doses
Endpoint domain: Adverse events/effects
Primary endpoint: preliminary anti-tumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thickness of the Echo Lucent Band (ELB) of the psoriatic infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxford Knee Score (AUC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gingival Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized Tissue Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Obstructive Sleep Apnea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Determine the severity of Sleep Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % of Patients With Non-surgical Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: % of Patients With Thromboembolic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Hyperparathyroidism at One Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical attachment level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiac biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of empowerment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in physical performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Off and On Medication Unified Parkinson's Disease Rating III Score (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total response of nausea and vomiting/retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With hSBA Titer >=1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean hSBA Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of serum estradiol suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lower Extremity Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meters Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Pain Inventory: Interference Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Brief Pain Inventory: Severity Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serious Adverse Reactions (SARs), Severe AEs and Important Medical Reactions (IMRs) Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Single Dose Seroprotection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pre-and post test pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urine pH from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in lab results (routine blood work) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax,ss: Maximum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt,ss: Area under the drug concentration-time curve within a dosing interval at steady states
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: negative emotional states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in breast size measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in bra size measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients completing adjuvant chemoradiotherapy and surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive prognosis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax: Maximum drug concentration in plasma after dose administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte phenotype comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nicotine Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Measured by EXAMINER Battery
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Feasibility Measured by Recruitment
Endpoint domain: Resource use
Endpoint subdomain: null
Primary endpoint: Safety Measured by Total Serious Adverse Events (SAEs) and Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Number of patients experiencing ≥ Grade 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing Grade 4 adverse events related to crenolanib
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of early mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Who Achieved SRH Area ≥25 mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain score using Premature Infant Pain Profile (PIPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes